

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 24/2017 on issuers of financial instruments and market operations, and the provisions of Article 99 of the Bucharest Stock Exchange Code, Title II, Issuers and Financial Instruments

Report Date: **27 January 2025**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**

Registered Office: **Bucharest, Calea Grivitei, no. 365, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J40/3709/1996**

Subscribed and paid-in share capital: **132,870,492 RON**

Total number of shares: **531,481,968 (out of which 427,042 shares without voting rights and 531,054,926 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Significant events to report:

Closed trading period: 29 January – 27 February 2025

MED LIFE S.A. informs investors that between 29 January and 27 February 2025, the persons who have access to privileged information („insiders”) according to the provisions of FSA Regulation no. 5/2018, Law no. 24/2017 and EU Regulations no. 522/2016 and no. 596/2014 respectively, do not have the right to carry out any transactions in their own name or on behalf of a third party, directly or indirectly, related to shares, bonds, securities, debt or other derivative financial instruments of the Company.

This closed trading period occurs as a result of the fact that on 28 February 2025, the Company will publish the 2024 Unaudited Preliminary Annual Financial Results.

Mihail Marcu
Chief Executive Officer